Investigating the cancer-causing potential of specific KRAS gene mutations in pancreatic cancer
Defining the oncogenic potential and therapeutic dependencies of PDAC-associated KRAS variants
This study is looking at how certain changes in the KRAS gene can lead to pancreatic cancer, with the hope of finding new ways to treat this tough disease by using special mouse models that act like human cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11058669 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly lethal cancer often diagnosed at advanced stages. It aims to understand how different mutations in the KRAS gene contribute to the development of PDAC and identify potential therapeutic targets. By using advanced mouse models that mimic human cancer mutations, the study will explore how these mutations affect pancreatic cell behavior and cancer progression. The goal is to uncover specific vulnerabilities associated with less common KRAS mutations that could lead to new treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, especially those with KRAS mutations.
Not a fit: Patients with pancreatic cancer who do not have KRAS mutations or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with pancreatic cancer, particularly those with specific KRAS mutations.
How similar studies have performed: Other research has shown promise in targeting KRAS mutations in cancer, but the specific focus on KRASG12R mutations in PDAC is relatively novel.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Chandwani, Rohit — Weill Medical Coll of Cornell Univ
- Study coordinator: Chandwani, Rohit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.